IMMUNOSTIMULATORY BACTERIAL ANTIGENS EXPRESSED IN ONCOLYTIC VIRAL PLATFORMS WILL BE TESTED IN PRECLINICAL MODELS OF GLIOBLASTOMA TO OVERCOME IMMUNE CHECKPOINT INHIBITOR RESISTANCE.

Pl: Evanthia Galanis, MD
Professor of Oncology and Sandra J. Schulze Professor of Novel Therapeutics
Mayo Clinic College of Medicine

Close Menu